Detectable Prostate-specific antigen value between 0.01 and 0.1 ng/ml following robotic-assisted radical prostatectomy (RARP): does it correlate with future biochemical recurrence?
| Autor: | Amr Hodhod, Côme Tholomier, Franziska Stolzenbach, David-Dan Nguyen, Cristina Negrean, Kevin C. Zorn, Ahmed S. Zakaria, Russell N Schwartz, Félix Couture, Pierre I. Karakiewicz, Marc Zanaty, Assaad El-Hakim, Hanna Shahine |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Nephrology
Biochemical recurrence Male medicine.medical_specialty Robotic assisted Urology medicine.medical_treatment 030232 urology & nephrology 03 medical and health sciences Prostate cancer 0302 clinical medicine Robotic Surgical Procedures hemic and lymphatic diseases Internal medicine medicine Humans Correlation of Data Aged Retrospective Studies Prostatectomy business.industry breakpoint cluster region Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Prognosis Prostate-specific antigen 030220 oncology & carcinogenesis Cohort Neoplasm Recurrence Local business |
| Zdroj: | World journal of urology. 39(6) |
| ISSN: | 1433-8726 |
| Popis: | The aim of the study is to evaluate the impact of having a nadir and persistently detectable ultrasensitive prostate-specific antigen (uPSA) between 0.01 and 0.1 ng/ml post-robot-assisted radical prostatectomy (RARP), on future biochemical recurrence (BCR). We conducted a retrospective analysis of a prospectively maintained cohort of 1359 men who underwent RARP, between 2006 and 2019. Patients were followed with uPSA at 1, 3, 6, 9, 12, 18, 24, 30, 36 months and annually thereafter. We included patients with PSA nadir values between 0.01 and 0.1 ng/ml within 6 months of surgery and with at least 2 follow-up measurements within the same range. We divided patients based on their BCR status and analyzed uPSA changes. Multivariable Cox-regression models (CRMs) were used to analyze variables predicting BCR-free survival (BCR-FS). We identified 167 (12.3%) patients for analyses, with a mean follow-up time of 60.2 ± 31.4 months. In our cohort, 5-year BCR-FS rate was 86%. Overall, 32 (19.1%) patients had BCR, with a mean time to BCR of 43.7 ± 24.3 months. BCR-free patients had stable mean uPSA values ≤ 0.033 ng/ml, while patients who developed BCR showed a slowly rising trend over time, with a significant difference between groups starting at 9 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink